# Endo Vitd Supplementation Pregnancy

> Suggests empiric vitamin D supplementation during pregnancy to lower the risk of preeclampsia, intra-uterine mortality, preterm birth, small-for-gestational-age birth, and neonatal mortality. Triggered by clinician questions such as "Should I prescribe vitamin D to this pregnant patient?" or "Is vitamin D supplementation indicated for pregnant patients?"

- Skill: `dromlakhani/endo-vitd-supplementation-pregnancy` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-vitd-supplementation-pregnancy`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-vitd-supplementation-pregnancy/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/endo-vitd-supplementation-pregnancy

---


# Vitamin D supplementation during pregnancy

## STEP 1 — Gather Information
Confirm pregnancy and gestational age; assess for contraindications (hypercalcemia, sarcoidosis, other granulomatous diseases) and established indications for vitamin D treatment (e.g., known deficiency requiring therapeutic dosing); review current prenatal vitamin intake. If pregnancy is confirmed and no contraindications/established indications exist, proceed to Step 2.

## STEP 2 — Rule In / Rule Out
Does the patient have any contraindication to vitamin D supplementation or an established indication for vitamin D treatment?  
- **Yes:** Do NOT proceed with empiric vitamin D supplementation for pregnancy indication (stop).  
- **No:** Proceed to Step 3.

## STEP 3 — Classify or Stratify
Classify the patient as a candidate for empiric vitamin D supplementation (pregnant, no contraindications, no established treatment indication).  
Decision: Move to supplementation decision.

## STEP 4 — Decide
Prescribe empiric vitamin D supplementation via daily intake of fortified foods, prenatal vitamin formulations containing vitamin D, and/or vitamin D supplement (pills or drops). No specific dose mandated; typical regimens in trials ranged 600–5000 IU daily equivalent, with weighted average ~2500 IU per day.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely on 25(OH)D testing to guide supplementation decisions; avoid in patients with hypercalcemia, sarcoidosis, or other granulomatous diseases; do not exceed the tolerable upper intake level (4000 IU/day for adults) without monitoring; do not replace standard prenatal vitamins that already contain adequate vitamin D; do not administer to patients with known vitamin D deficiency requiring therapeutic repletion regimens.

## Concrete Clinical Example
A 28-year-old G1P0 at 16 weeks gestation asks, "Should I take vitamin D?" She has no history of hypercalcemia, sarcoidosis, or other contraindications, and takes a standard prenatal vitamin with 400 IU vitamin D. After confirming pregnancy and absence of contraindications, the clinician suggests adding empiric vitamin D supplementation (e.g., an additional 1000–2000 IU daily) to potentially lower risk of preeclampsia and adverse perinatal outcomes.

**Source:** Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2024, https://doi.org/10.1210/clinem/dgae290